Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Intrinsic Value

AGY price has not been updated for more than 3 weeks. This may indicate that the stock has been delisted.
AGY's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AGY stock under the Base Case scenario is 4.33 GBX. Compared to the current market price of 6.25 GBX, Allergy Therapeutics PLC is Overvalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Allergy Therapeutics PLC

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
AGY
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for AGY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about AGY?
Bearish
Neutral
Bullish

Fundamental Analysis

6.25 GBX
-0.79%
-0.79%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Allergy Therapeutics PLC
UK
Pharmaceuticals
Market Cap
297.9m GBX
IPO
Oct 11, 2004
Employees
601
United Kingdom
Market Cap
297.9m GBX
Industry
Pharmaceuticals
IPO
Oct 11, 2004
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Allergy Therapeutics PLC

Provide an overview of the primary business activities
of Allergy Therapeutics PLC.

What unique competitive advantages
does Allergy Therapeutics PLC hold over its rivals?

What risks and challenges
does Allergy Therapeutics PLC face in the near future?

Has there been any significant insider trading activity
in Allergy Therapeutics PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Allergy Therapeutics PLC.

Provide P/S
for Allergy Therapeutics PLC.

Provide P/E
for Allergy Therapeutics PLC.

Provide P/OCF
for Allergy Therapeutics PLC.

Provide P/FCFE
for Allergy Therapeutics PLC.

Provide P/B
for Allergy Therapeutics PLC.

Provide EV/S
for Allergy Therapeutics PLC.

Provide EV/GP
for Allergy Therapeutics PLC.

Provide EV/EBITDA
for Allergy Therapeutics PLC.

Provide EV/EBIT
for Allergy Therapeutics PLC.

Provide EV/OCF
for Allergy Therapeutics PLC.

Provide EV/FCFF
for Allergy Therapeutics PLC.

Provide EV/IC
for Allergy Therapeutics PLC.

Show me price targets
for Allergy Therapeutics PLC made by professional analysts.

What are the Revenue projections
for Allergy Therapeutics PLC?

How accurate were the past Revenue estimates
for Allergy Therapeutics PLC?

What are the Net Income projections
for Allergy Therapeutics PLC?

How accurate were the past Net Income estimates
for Allergy Therapeutics PLC?

What are the EPS projections
for Allergy Therapeutics PLC?

How accurate were the past EPS estimates
for Allergy Therapeutics PLC?

What are the EBIT projections
for Allergy Therapeutics PLC?

How accurate were the past EBIT estimates
for Allergy Therapeutics PLC?

Compare the revenue forecasts
for Allergy Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Allergy Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Allergy Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Allergy Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Allergy Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Allergy Therapeutics PLC with its peers.

Analyze the financial leverage
of Allergy Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Allergy Therapeutics PLC.

Provide ROE
for Allergy Therapeutics PLC.

Provide ROA
for Allergy Therapeutics PLC.

Provide ROIC
for Allergy Therapeutics PLC.

Provide ROCE
for Allergy Therapeutics PLC.

Provide Gross Margin
for Allergy Therapeutics PLC.

Provide Operating Margin
for Allergy Therapeutics PLC.

Provide Net Margin
for Allergy Therapeutics PLC.

Provide FCF Margin
for Allergy Therapeutics PLC.

Show all solvency ratios
for Allergy Therapeutics PLC.

Provide D/E Ratio
for Allergy Therapeutics PLC.

Provide D/A Ratio
for Allergy Therapeutics PLC.

Provide Interest Coverage Ratio
for Allergy Therapeutics PLC.

Provide Altman Z-Score Ratio
for Allergy Therapeutics PLC.

Provide Quick Ratio
for Allergy Therapeutics PLC.

Provide Current Ratio
for Allergy Therapeutics PLC.

Provide Cash Ratio
for Allergy Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Allergy Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Allergy Therapeutics PLC?

What is the current Free Cash Flow
of Allergy Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Allergy Therapeutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Allergy Therapeutics PLC

Current Assets 35.3m
Cash & Short-Term Investments 13.5m
Receivables 9.9m
Other Current Assets 11.9m
Non-Current Assets 33.7m
Long-Term Investments 5.3m
PP&E 23.4m
Intangibles 5m
Current Liabilities 25.3m
Accounts Payable 20.1m
Other Current Liabilities 5.2m
Non-Current Liabilities 17.3m
Long-Term Debt 8.1m
Other Non-Current Liabilities 9.2m
Efficiency

Earnings Waterfall
Allergy Therapeutics PLC

Revenue
53.3m GBP
Cost of Revenue
-25.3m GBP
Gross Profit
28m GBP
Operating Expenses
-66.8m GBP
Operating Income
-38.8m GBP
Other Expenses
-11.4m GBP
Net Income
-50.2m GBP

Free Cash Flow Analysis
Allergy Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AGY Profitability Score
Profitability Due Diligence

Allergy Therapeutics PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
17/100
Profitability
Score

Allergy Therapeutics PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

AGY Solvency Score
Solvency Due Diligence

Allergy Therapeutics PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
38/100
Solvency
Score

Allergy Therapeutics PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGY Price Targets Summary
Allergy Therapeutics PLC

Wall Street analysts forecast AGY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGY is 13.26 GBX with a low forecast of 13.13 GBX and a high forecast of 13.65 GBX.

Lowest
Price Target
13.13 GBX
110% Upside
Average
Price Target
13.26 GBX
112% Upside
Highest
Price Target
13.65 GBX
118% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AGY?

Click here to dive deeper.

Dividends

Allergy Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AGY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AGY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

See Also

Discover More
What is the Intrinsic Value of one AGY stock?

The intrinsic value of one AGY stock under the Base Case scenario is 4.33 GBX.

Is AGY stock undervalued or overvalued?

Compared to the current market price of 6.25 GBX, Allergy Therapeutics PLC is Overvalued by 31%.

Back to Top